SEC Form 4 · accession 0001717590-18-000001
OSIRIS THERAPEUTICS, INC. · OSIR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Keefer
Officer — Interim President and CEO
Period of report
Jun 26, 2018
Accepted (ET)
Jun 28, 2018 · 4:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001360886
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1 | $10.53 | Jun 26, 2018 | A | 20,000 | A | Jun 26, 2019 | Jun 26, 2028 | Common Stock | 20,000 | 36,000 | D |
Explanation of responses
- F125% of the shares underlying this option shall vest on each of June 26, 2019, June 26, 2020, June 26, 2021 and June 26, 2022, subject to Reporting Person's continued service through the applicable vesting date.